NARVALUS Srl IS PLEASED TO ANNOUNCE THE LAUNCH OF THE `T2 TARGET TRANSFECTOR`
Released on = September 26, 2006, 4:47 am
Press Release Author = cinzia bersani
Industry = Biotech
Press Release Summary = A NEW TECHNOLOGY FOR TRANSFECTING ADHERENT CELLS ON MICROCHIP
Press Release Body = Colleretto Giacosa (TO) Italy, September 27, 2006
Narvalus Srl is pleased to announce the conclusion of all the prototype activities of its proprietary technology which lead to the definition of "T2 Target Transfector".
The "T2 Target Transfector" will be presented today at the Bioindustry Park Canavese SpA. Narvalus technology consists of electroporating single cells cultivated on microchip through micro electrodes positioned on the chip itself.
Compared to the traditional methods, this technology and its specific equipment, allows individual and immediate response. The ability to address single cells, the high flexibility in the pulse design and the instantaneous experiment read-out, enables the operator to obtain a quick optimization of the electroporation protocol. The T2 technology gives high reproducibility of the transfection rates, allowing furthermore the check of each single cell behaviour after transfection.
The technology has been tested on different cell lines and it has been shown to be widely versatile since the transfection method could be easily defined and modified by the operator: it has been validated for the introduction of dyes, oligonucleotides (extremely appropriate for siRNA studies) and plasmids.
In the biotechnological field, electroporation is employed for cell transfection and represents the basic process of the biotechnological techniques.
The "T2 Target Transfector" represents in this field a relevant innovation and it gives unexplored opportunities both for research in molecular biology and diagnostic/industrial applications.
"The T2 Target Transfector presented today at the Bioindustry Park Canavese is an important result for our research group," says Manfredi Manfrin Ceo of the Narvalus Biotech Srl" and we hope it will quickly find applications at academic and industrial research labs thanks to its potential versatility and simplicity".
Narvalus Biotech Narvalus Biotech srl was constituted in 2005, (operative since autumn 2005), located at the Bioindustry Park Incubator, financially supported by Eporgen Venture SpA.
The technology, originally created and developed at Rovereto (Biosilab Srl), has been selected through the Discovery program with the aim of setting up Narvalus Company whose focus consists in transferring the technology from lab to market.
2022
